June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Clinical features associated with steroid-induced ocular hypertensive response in eyes with refractory allergic ocular diseases with proliferative lesions or corneal involvement
Author Affiliations & Notes
  • Dai Miyazaki
    Ophthalmology, Tottori University, Yonago, Japan
  • Atsuki Fukushima
    Kochi Medical School, Kochi, Japan
  • Yuichi Ohashi
    Ehime University School of Medicine, Toon, Japan
  • Eiichi Uchio
    Fukuoka University, School of Medicine, Fukuoka, Japan
  • Naoki Kumagai
    Kumagai Eye Clinic, Yamaguchi, Japan
  • Jun Shoji
    Nihon University School of Medicine, Tokyo, Japan
  • Etsuko Takamura
    Tokyo Women’s Medical University School of Medicine, Tokyo, Japan
  • Yayoi Nakagawa
    Nakagawa Eye Clinic, Osaka, Japan
  • Kenichi Namba
    Hokkaido University Graduate School of Medicine, Sapporo, Japan
  • Hiroshi Fujishima
    Opthalmology, Tsurumi University Dental Hospital, Kanagawa, Japan
  • Footnotes
    Commercial Relationships Dai Miyazaki, None; Atsuki Fukushima, None; Yuichi Ohashi, None; Eiichi Uchio, None; Naoki Kumagai, None; Jun Shoji, None; Etsuko Takamura, None; Yayoi Nakagawa, None; Kenichi Namba, None; Hiroshi Fujishima, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 4884. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Dai Miyazaki, Atsuki Fukushima, Yuichi Ohashi, Eiichi Uchio, Naoki Kumagai, Jun Shoji, Etsuko Takamura, Yayoi Nakagawa, Kenichi Namba, Hiroshi Fujishima; Clinical features associated with steroid-induced ocular hypertensive response in eyes with refractory allergic ocular diseases with proliferative lesions or corneal involvement. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):4884.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To identify clinical factors significantly associated with steroid-induced ocular hypertension in refractory allergic ocular diseases with proliferative lesion or corneal involvement.

Methods: The 1436 refractory allergic ocular disease patients enrolled for topical tacrolimus treatment trial were retrospectively analyzed. Of the 1436 eyes treated with topical tacrolimus, 410 patients necessitated with topical steroids in conjunction during the 3 months follow up, were analyzed.<br /> The baseline intraocular pressures (IOP) were measured, and the clinical signs were rated on a 4 grade scale. The change in the IOP (ΔIOP) during the follow up were calculated by subtracting the base line from the maximum IOP. Patients responded with ≥ third quartile of IOP change was defined as steroid-induced hypertensive.

Results: The mean ΔIOP was 0.72 ± 0.17 mmHg (median, 0 mmHg; third quartile, 3 mmHg). The incidence of giant papillae was significantly higher for patients who had steroid-induced hypertension (P=0.0007). The IOP elevation was inversely correlated with age (ρ=-0.142, P<0.005), and the incidence of IOP elevation was significantly higher in patients without eczema (P<0.05). Logistic analysis on the ocular hypertensive responders showed that eyes with giant papillae had a significant high OR of 3.43 for the maximum score after age adjustments (95% confidence interval, 1.57-7.49; P=0.002). The area under the receiver operating characteristic curve for prediction of ocular hypertensive response was 0.60, 0.54, and 0.56 for giant papilla, younger age (≤median), and eyes without eczema, respectively.

Conclusions: Refractory allergic eyes with giant papillae, without eczema, and younger age were significantly associated with positive ocular hypertensive response. These findings may help to predict eyes that will have steroid-induced hypertension.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×